NCT03215069View on ClinicalTrials.gov

Empagliflozin and the Preservation of Beta-cell Function in Women with Recent Gestational Diabetes

PHASE3CompletedINTERVENTIONAL

Enrollment

91

Participants

Timeline

Start Date

July 1, 2018

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions

Gestational Diabetes

Interventions

DRUG

Empagliflozin 10 MG

Empagliflozin 10 mg PO daily

DRUG

Placebo oral capsule

Placebo PO daily

Trial Locations (1)

M5T 3L9

Leadership Sinai Centre foe Diabetes - Mount Sinai Hospital, Toronto

Sponsors

Collaborators (1)

Boehringer Ingelheim

All Listed Sponsors

collaborator

Boehringer Ingelheim

INDUSTRY

lead

Mount Sinai Hospital, Canada

OTHER

NCT03215069 - Empagliflozin and the Preservation of Beta-cell Function in Women with Recent Gestational Diabetes | Biotech Hunter | Biotech Hunter